Qnexa American Diabetes Association 70th Scientific Sessions
- Magnitude of Weight Loss Experienced With a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate May Drive Degree of Cardiometabolic Benefit
- Improvements in Dyslipidemia and Other Cardiometabolic Disease Risk Factors With Low-Dose, Controlled-Release Phentermine/Topiramate
- Changes in Insulin Sensitivity and Insulin Secretion in Overweight/Obese Patients Treated With Low-Dose, Controlled-Release Phentermine/Topiramate
- Low-Dose, Controlled-Release Phentermine/Topiramate and Markers of Type 2 Diabetes Mellitus
- Effects of Low-Dose, Controlled-Release Phentermine/Topiramate on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus
- A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients With Type 2 Diabetes Mellitus or Prediabetes: the CONQUER Trial
Associated Professional Sleep Societies
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Phentermine/Topiramate CR (VI-0521) for the Treatment of Obstructive Sleep Apnea/Hypopnea Syndrome in Obese Adults
Avanafil American Urological Assocation 2010 Annual Meeting
Investigating Avanafil in the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial
Qnexa 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) - May 15, 2010
Weight Loss With Controlled-Release Phentermine-Topiramate (PHEN/TPM CR) Drives Improvements in Obesity-Related Comorbidities in Overweight and Obese Subjects Over 12 Months Treatment
Qnexa EuroPRevent 2010 - May 5, 2010
- 12-Month Weight Loss and Triglyceride Changes With PHEN/TPM CR in Overweight and Obese Subjects With Hypertriglyceridemia
- 12-Month Weight Loss and Antihypertensive Benefits With PHEN/TPM CR in Overweight and Obese Subjects With Hypertension
Qnexa American Society of Hypertension 25th Annual Scientific Meeting and Exposition - May 4, 2010
Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Improves Blood Pressure and Results in Weight Loss in Overweight/Obese Patients Through 28 Weeks
Qnexa EASD EASD Presentation in Vienna
October 2, 2009
Qnexa
Qnexa Phase 3 Results Conference Call
September 9, 2009
Qnexa ADA
 Weight Loss with VI-0521 Stops Progression Toward Type 2 Diabetes in Obese Non-diabetic Subjects
June, 2009
Qnexa ADA Can Weight Loss Treat Diabetes? Results of One-Year of Treatment with VI-0521 in Obese Type 2 Diabetics
June, 2009
Qnexa NAASO Long-Term Follow-Up of Phentermine with Topiramate for Obesity in Clinical Practice
Qnexa NAASO Changes in Weight and Quality of Life in Obese Adults Treated with Topiramate Plus Phentermine
Qnexa ADA The Weight Effects of VI-0521 in Type 2 Diabetes
Qnexa ADA Effect of VI-0521 (Phentermine and Topiramate) in Type 2 Diabetes (Abstract)
Avanafil SMSNA Safety and Efficacy of Avanafil, A new PDE5 Inhibitor for Treating Erectile Dysfunction
Avanafil SMSNA Hemodynamic Effects of Co-Administration of Avanafil and Glyceryl Trinitrate
Avanafil SMSNA Pharacokinetics of Avanafil, a New PDE5 Inhibitor Being Developed for Treating Erectile Dysfunction
PDF Print E-mail  
© 2010 VIVUS Inc. All rights reserved.